CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Lilly-backed Orbis does up to $1.4B macrocycle deal with Novo

PartnershipPositive
AI Analysis

Summary

Orbis Medicines, backed by Eli Lilly, entered into an up to $1.4 billion alliance with Novo to develop macrocycle molecules for cardiometabolic diseases.

Importance:7/10
Sentiment:
0.60
partnershipmacrocyclescardiometabolicOrbis MedicinesNovoEli Lilly
Related Companies

Read the original article

Published by Endpoints News on September 17, 2026 11:00 AM

Read Original